Web1 day ago · Title: NETSseq platform identifies KCNK13 (THIK-1) as a target to modulate neuroinflammation in Alzheimer's disease ... Cerevance is a private pharmaceutical company with a focus on CNS disorders ... WebNov 30, 2024 · Cerevance’s THIK-1 targeting inhibitor, C101248, demonstrated positive results in human and mouse cell based and electrophysiology assays relevant to neuroinflammation inneurodegenerative disease Data has been concurrently published in the peer-reviewed journal, Neuropharmacology
In-Depth News at Cerevance
WebCerevance today announced a poster presentation at the BritishNeuroscience Association (BNA) 2024 International Festival of Neuroscience inBrighton, United Kingdom being held April 23-26, 2024 ... Title: NETSseq platform identifies KCNK13 (THIK-1) as a target to modulate neuroinflammation in Alzheimer’s disease . Overview: The NETSseq ... WebMar 27, 2024 · November 15, 2024 08:00 ET Source: Cerevance – Data demonstrated C101248 is a promising inhibitor of THIK-1, an emerging target in Alzheimer’s disease –– THIK-1 was identified using... is buzzy cohen the new host of jeopardy
Cerevance Announces Presentation of Preclinical Data During the …
WebApr 13, 2024 · Cerevance. BOSTON, April 13, 2024 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, today announced ... WebNov 15, 2024 · BOSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous … WebOverall, these data suggest that THIK-1 is a regulator of NLRP3 inflammasome activation in response to ATP and identify THIK-1 as a potential therapeutic target for inflammatory disease. Keywords: NLRP3; THIK-1; inflammasome; inflammation; interleukin-1; potassium channel. © 2024 The Authors. GLIA published by Wiley Periodicals LLC. is buzzy cohen on the chase